Publix to offer Bioject ZetaJet for flu immunizations

Bioject Medical Technologies Inc. (OTCBB:BJCT), a leading developer of needle-free injection therapy systems, announced today that beginning in September 2011, select Publix Super Markets (Publix) in the Southeast region will be offering flu season immunizations utilizing the Bioject®ZetaJet™. Publix will be conducting evaluations in 52 stores in Florida, Georgia, Alabama and South Carolina.

“We are pleased that Publix has chosen to offer the Bioject®ZetaJet™ spring-powered device, Bioject's latest advance in needle-free delivery, for this year's flu immunizations”

"We are pleased that Publix has chosen to offer the Bioject®ZetaJet™ spring-powered device, Bioject's latest advance in needle-free delivery, for this year's flu immunizations," said Dr. Richard Stout, Executive Vice President and Chief Medical Officer of Bioject. "The ergonomically- designed Bioject®ZetaJet™ provides patients a convenient alternative to the needle and syringe for the administration of the flu vaccine," added Dr. Stout.

The Bioject®ZetaJet™, Bioject's latest advance in needle-free delivery systems, consists of two components, the portable injector and an auto-disabling disposable syringe. It is intended to deliver vaccines and injectable medications up to 0.5 mL either subcutaneously or intramuscularly. The syringe assembly has a unique "auto-disable" feature that prevents its re-use.

Source:

Bioject Medical Technologies Inc.,

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Review highlights failures in global control strategies for bird flu transmission